Should I buy or sell ORIC Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORIC shares. View ORIC analyst ratings or view top-rated stocks .

What is ORIC Pharmaceuticals' stock price target for 2024?

7 equities research analysts have issued 12 month price targets for ORIC Pharmaceuticals' stock. Their ORIC share price targets range from $13.00 to $27.00. On average, they anticipate the company's stock price to reach $16.29 in the next year. This suggests a possible upside of 96.9% from the stock's current price. View analysts price targets for ORIC or view top-rated stocks among Wall Street analysts .

How have ORIC shares performed in 2023?

ORIC Pharmaceuticals' stock was trading at $5.89 at the start of the year. Since then, ORIC stock has increased by 40.4% and is now trading at $8.27. View the best growth stocks for 2023 here .

When is ORIC Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our ORIC earnings forecast .

How were ORIC Pharmaceuticals' earnings last quarter?

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.02.

What other stocks do shareholders of ORIC Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE) , Intel (INTC) , CrowdStrike (CRWD) , Valero Energy (VLO) , Hello Group (MOMO) , ONEOK (OKE) , DocuSign (DOCU) , Vaxart (VXRT) , Delta Air Lines (DAL) and Datadog (DDOG) .

When did ORIC Pharmaceuticals IPO?

(ORIC) raised $75 million in an initial public offering on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO.

Who are ORIC Pharmaceuticals' major shareholders?

ORIC Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Alkeon Capital Management LLC (6.38%), FMR LLC (5.74%), Silverarc Capital Management LLC (2.06%), Euclidean Capital LLC (1.81%), Vivo Capital LLC (1.43%) and Monaco Asset Management SAM (0.71%). Insiders that own company stock include Carl L Gordon , Dominic Piscitelli, Jacob Chacko , Orbimed Advisors Llc, Pratik S Multani, Richard A Heyman, Richard A Heyman and Richard H Scheller . View institutional ownership trends .

How do I buy shares of ORIC Pharmaceuticals?

Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

ORIC Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ORIC)

$8.27

+0.37 (+4.68%)

(As of 12/1/2023 ET)

Compare

Today's Range: $7.65
▼
$8.30
50-Day Range: $5.41
▼
$8.27
52-Week Range: $2.91
▼
$9.79

Volume: 406,163 shs
Average Volume: 339,532 shs
Market Capitalization: $451.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.29

ORIC Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 96.9% Upside
$16.29 Price Target
Short Interest: Bearish
28.09% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.65
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.96) to ($2.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

543rd out of 950 stocks

Pharmaceutical Preparations Industry

257th out of 437 stocks

3.5

Analyst's Opinion

Consensus Rating
ORIC Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.29, ORIC Pharmaceuticals has a forecasted upside of 96.9% from its current price of $8.27.
Amount of Analyst Coverage
ORIC Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
28.09% of the float of ORIC Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
ORIC Pharmaceuticals has a short interest ratio ("days to cover") of 20.3, which indicates bearish sentiment.
Change versus previous month
Short interest in ORIC Pharmaceuticals has recently increased by 14.94%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ORIC Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ORIC Pharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ORIC Pharmaceuticals has received a 73.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for ORIC Pharmaceuticals is -0.65.

2.2

News and Social Media Coverage

News Sentiment
ORIC Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for ORIC Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added ORIC Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ORIC Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.34% of the stock of ORIC Pharmaceuticals is held by insiders.
Percentage Held by Institutions
91.30% of the stock of ORIC Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for ORIC Pharmaceuticals are expected to decrease in the coming year, from ($1.96) to ($2.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ORIC Pharmaceuticals is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ORIC Pharmaceuticals is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ORIC Pharmaceuticals has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ORIC Pharmaceuticals Stock (NASDAQ:ORIC)

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ORIC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ORIC Stock News Headlines

November 24, 2023 | americanbankingnews.com

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Buy" from Analysts

November 9, 2023 | morningstar.com

ORIC Pharmaceuticals Inc ORIC

December 2, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL), Oric Pharmaceuticals (ORIC) and Acadia Healthcare (ACHC)

November 6, 2023 | msn.com

ORIC Pharmaceuticals GAAP EPS of -$0.44

November 6, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Inc (ORIC) Reports Q3 2023 Financial Results and Operational Updates

November 6, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

November 2, 2023 | finance.yahoo.com

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

October 23, 2023 | msn.com

Wedbush Reiterates ORIC Pharmaceuticals (ORIC) Outperform Recommendation

October 23, 2023 | markets.businessinsider.com

Analyst Expectations for ORIC Pharmaceuticals's Future

October 21, 2023 | finance.yahoo.com

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

October 17, 2023 | finance.yahoo.com

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

October 16, 2023 | finance.yahoo.com

Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?

September 26, 2023 | finance.yahoo.com

NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD

September 20, 2023 | benzinga.com

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

September 20, 2023 | finance.yahoo.com

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

September 13, 2023 | msn.com

Navigating ORIC's Robust Strategy Against Cancer Drug Resistance

August 17, 2023 | markets.businessinsider.com

Oric Pharmaceuticals (ORIC) Receives a Buy from Robert W. Baird

August 16, 2023 | msn.com

Baird Maintains ORIC Pharmaceuticals (ORIC) Outperform Recommendation

August 15, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)

August 11, 2023 | msn.com

Markets Today: Stocks Fall on a Hot U.S. July PPI

August 11, 2023 | msn.com

ORIC Pharmaceuticals GAAP EPS of -$0.50 beats by $0.08

August 11, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

August 4, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 28, 2023 | markets.businessinsider.com

Why Oric Pharmaceuticals Stock Is Shooting Higher Today

June 26, 2023 | finance.yahoo.com

Why Shares of Oric Pharmaceuticals Jumped Monday

See More Headlines

Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ORIC
CUSIP: N/A
CIK: 1796280
Web: www.oricpharma.com
Phone: 650-388-5600
Fax: N/A
Employees: 93
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.29
High Stock Price Target: $27.00
Low Stock Price Target: $13.00
Potential Upside/Downside: +96.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.99)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-89,120,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -39.61%
Return on Assets: -35.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.26
Quick Ratio: 12.26

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.54 per share
Price / Book: 1.82

Miscellaneous

Outstanding Shares: 54,550,000
Free Float: 51,638,000
Market Cap: $451.13 million
Optionable: Not Optionable
Beta: 0.88

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Richard A. Heyman Ph.D. (Age 66)
Co-Founder, Independent Chairman & Member of Scientific Advisory Board
Comp: $93k
Dr. Jacob M. Chacko M.B.A. (Age 44)
M.D., President, CEO & Director
Comp: $921.32k
Mr. Dominic G. Piscitelli CPA (Age 48)
M.B.A., Chief Financial Officer
Comp: $636.91k
Dr. Pratik S. Multani M.D. (Age 56)
M.S., Chief Medical Officer
Comp: $686.88k
Dr. Charles L. Sawyers B.A. (Age 64)
M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board
Dr. Scott W. Lowe Ph.D.
Co-Founder & Member of Scientific Advisory Board
Dr. Lori Sickels Friedman Ph.D. (Age 59)
Chief Scientific Officer
Dr. Christian V. Kuhlen Esq. (Age 50)
J.D., M.D., General Counsel
Mr. Daniel Iazzetti
VP & Head of People
Dr. Edna Chow Maneval (Age 63)
Senior Vice President of Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ORIC Stock Analysis - Frequently Asked Questions

Should I buy or sell ORIC Pharmaceuticals stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORIC shares.
View ORIC analyst ratings or view top-rated stocks.
What is ORIC Pharmaceuticals' stock price target for 2024?: 7 equities research analysts have issued 12 month price targets for ORIC Pharmaceuticals' stock. Their ORIC share price targets range from $13.00 to $27.00. On average, they anticipate the company's stock price to reach $16.29 in the next year. This suggests a possible upside of 96.9% from the stock's current price.
View analysts price targets for ORIC or view top-rated stocks among Wall Street analysts.
How have ORIC shares performed in 2023?: ORIC Pharmaceuticals' stock was trading at $5.89 at the start of the year. Since then, ORIC stock has increased by 40.4% and is now trading at $8.27.
View the best growth stocks for 2023 here.
When is ORIC Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our ORIC earnings forecast.
How were ORIC Pharmaceuticals' earnings last quarter?: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.02.

What other stocks do shareholders of ORIC Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG).
When did ORIC Pharmaceuticals IPO?: (ORIC) raised $75 million in an initial public offering on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO.
Who are ORIC Pharmaceuticals' major shareholders?: ORIC Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Alkeon Capital Management LLC (6.38%), FMR LLC (5.74%), Silverarc Capital Management LLC (2.06%), Euclidean Capital LLC (1.81%), Vivo Capital LLC (1.43%) and Monaco Asset Management SAM (0.71%). Insiders that own company stock include Carl L Gordon, Dominic Piscitelli, Jacob Chacko, Orbimed Advisors Llc, Pratik S Multani, Richard A Heyman, Richard A Heyman and Richard H Scheller.
View institutional ownership trends.
How do I buy shares of ORIC Pharmaceuticals?: Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ORIC) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial